Aicuris has reported the success of a phase 3 trial, which has demonstrated the superiority of oral antiviral pritelivir ...

Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking ...

A well-established diabetes drug alleviated brain inflammation in a female mouse model of multiple sclerosis, suggesting that ...

After charting several related moves earlier this year, Boehringer Ingelheim is returning to the antibody-drug conjugate well ...

In her role, Bumpus will serve as a part-time strategic advisor to Charles River, a spokesperson for the company told Fierce ...

The latest strand in Pelage Pharmaceuticals’ growing funds comes from a $120 million series B fundraising round that the ...

Medical devices continue to be a strong growth driver for Abbott, as the company battles its ongoing sales slump in ...

Specifically, New Amsterdam will use Caristo’s AI-powered CaRi-Heart and CaRi-Plaque technology to evaluate the efficacy of ...

As Tubulis prepares to unveil the first in-human data on its next-generation antibody drug conjugate (ADC) later this month, ...

After Omeros decided to hit pause on developing its MASP-3 inhibitor zaltenibart, Novo Nordisk has spied an opportunity to scoop up the rare disease drug.

Kailera Therapeutics has raised $600 million to take its lead obesity program into phase 3. The series B round continues the ...

Two years after spinning off its $15 billion consumer health unit as Kenvue, Johnson & Johnson is slimming down again by ...